Business, Policy

New year, new tax rates. How did the world’s biggest drugmakers fare?

Biopharma is bursting with reports this month of how Trumpian tax breaks will affect the industry’s biggest players, with AbbVie’s {$ABBV} jaw-dropping 50% rate slash winning the award for most notable headline. Big Pharma joined the parade shortly thereafter, each touting tax rate projections that equate to big money on the books for 2018.

We collected reports from 13 of the biggest drugmakers affected by the US corporate tax cut — all with revenues in the double-digit billions — to gauge the average impact of the new law on Big Pharma (full list below).

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 29,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Primer Toronto 2018

Head of DMPK, Director
Magenta Therapeutics Cambridge, MA
Research Scientist - Disease Biology & Cellular Pharmacology
Recursion Pharmaceuticals Salt Lake City
Sr/Medical Director, Medical Affairs
A Rare Disease Biotech New Brunswick, NJ
VP, Pharmacovigilance
Aeglea BioTherapeutics Austin, TX
Process Scientist/Lead
Tmunity Therapeutics Philadelphia, PA

Visit Endpoints Careers ->